{"schema_version":"secwatch.filing_event.v1","accession":"0001079973-26-001006","form_type":"8-K","ticker":"TOI","cik":"0001799191","company_name":"Oncology Institute, Inc.","filed_at":"2026-08-06T20:32:33+00:00","discovered_at":"2026-08-06T20:34:34.923586+00:00","generated_at":"2026-08-06T20:35:13.964421+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Starling Oncology Q2 revenue up 34.6% to $161.3M; raises FY2026 guidance","bullets":["Revenue $161.3M (+34.6% YoY); gross profit $27.2M (+55.2%).","Net loss narrowed to $9.8M from $17.0M; EPS $(0.08) vs $(0.15).","Adjusted EBITDA turned positive at $229K vs $(4.1M) loss in prior year.","Specialty Pharmacy revenue up 58% YoY; added ~230,000 capitated lives in California.","Raised full-year 2026 revenue and gross profit guidance."],"urls":{"canonical":"https://secwatch.observer/filing/0001079973-26-001006","json":"https://secwatch.observer/filing/0001079973-26-001006.json","markdown":"https://secwatch.observer/filing/0001079973-26-001006.md","text":"https://secwatch.observer/filing/0001079973-26-001006.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1799191/000107997326001006/0001079973-26-001006-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1799191/000107997326001006/stln_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T20:35:13.964421+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}